No Data
Private Companies Invested in Cryofocus Medtech (Shanghai) Co., Ltd. (HKG:6922) Copped the Brunt of Last Week's HK$466m Market Cap Decline
Kangfeng Biological - B [06922] is currently reported at 6.64 Hong Kong dollars, with a decline of 13.20%.
As of 15:07, Kangfeng Biotech - B [06922] is priced at 6.64 HKD, down 1.01 HKD or 13.20% from yesterday's closing price of 7.65 HKD, with a transaction value of 0.0804 million HKD. Today's highest price is 7.69 HKD, and the lowest price is 6.97 HKD. Based on yesterday's closing price, the 10-day average price is 7.88 HKD, the 50-day average price is 7.26 HKD, the current PE is -17.02 times, and the 14-day strength index is 30.53.
Cryofocus Medtech's Subsidiary to Collaborate on Research, Development of Cryoballoon Ablation for Lung Cancer
Kangrun Biotech-B (06922.HK): Signed a research cooperation agreement with the Guangzhou National Laboratory and the First Affiliated Hospital of Guangzhou Medical University.
October 16th, KeLonHui丨Kanglong Biological-B (06922.HK) issued an announcement that its wholly-owned subsidiary Ningbo Shengjie Kang Biological Technology Co., Ltd. ("Ningbo Shengjie Kang") will participate in the establishment and management of a research project in Guangzhou National Laboratory together with the First Affiliated Hospital of Guangzhou Medical University. Ningbo Shengjie Kang and Guangzhou National Laboratory, as well as the First Affiliated Hospital of Guangzhou Medical University, have recently signed a research cooperation agreement ("Research Cooperation Agreement") on the aforementioned project. Guangzhou National Laboratory is a new research institution in the field of respiratory system diseases and prevention, and is the core scientific and technological force in the field of respiratory system diseases. Guangzhou Medical
CRYOFOCUS-B: INTERIM REPORT 2024
Cryofocus Medtech Converts Over 29 Million Unlisted Shares to H Shares
